These features underpinned our strategy of combining the gold standard for anti-TNF therapy adalimumab (6) with scFv-A7 for functional tissue-specific delivery in a BsAb format, providing proof of concept in RA. The gene discussed is TNF; the disease is rheumatoid arthritis.